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EDITORIAL
Why  computational  methods  for  the study  of  biological
macromolecules and  their  effectors?
¿Por  qué  utilizar  métodos  computacionales  para  el  estudio
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Perhaps  we  should  start  this  editorial  by  raising  the  fol-
lowing  question:  Why  appeal  to  theoretical  approaches  for
studying  biological  macromolecules  and  the  effectors  with
therapeutic  potential?  Let  us  take  the  time  to  look  at  some
statistics  concerning  the  biological  databases.  As  of  June
2016,  there  were  around  9000  completed  and  published
genome  sequences  (archaea,  prokaryotes,  and  eukaryotes)
including  strains  or  varieties  of  the  same  species  (GOLD
database,  https://gold.jgi.doe.gov/).
The  exponential  growth  of  sequenced  genomes  has  kept
steady  over  the  past  15  years.  On  another  hand,  the  growth
of  the  databanks  containing  protein  sequences  doubles
in  less  than  1.5  years.  As  a  result,  there  are  more  than
15  million  protein  sequences  at  50%  sequence  identity  in
the  UniProt  database  (http://www.uniprot.org/).  However,
the  growth  of  the  databank  of  the  3D  structures  of  proteins,
PDB  (http://www.rcsb.org/pdb/),  is  several  orders  of  mag-
nitude  smaller  (10-3).  As  it  is,  the  number  of  non-redundant
sequences  in  the  PDB  database  at  30%  sequence  identity
is  of  approximately  only  26000;  not  to  mention  that  the
overall  number  of  membrane  protein  structures  (pharma-
cological  targets  par  excellence)  remains  small  in  spite
of  recent  experimental  advances  in  the  determination  of
their  3D  structure;  it  only  reaches  less  than  300  redundant
structures  in  the  PDB.  Accordingly,  there  is  an  increasing
need  to  develop  and  apply  in  silico  methods  to  obtain
reliable  3D  molecular  models,  given  that  the  experimental
determination  of  the  3D  structures  of  all  sequences  is
impossible  on  the  one  hand,  and  useless  on  the  other  hand.
Indeed,  nowadays  there  are  computational  methods  that
can  generate  reliable  3D  models  in  a  reasonable  amount  of
time  for  a  large  number  of  protein  sequences,  without  hav-
ing  to  perform  the  experimental  structure  determination.
This  theoretical  approach  leads  to  saving  time  and  money.
For  example,  the  IDC  market  research  ﬁrm  indicated  that
for  $1  invested  in  modeling  and  simulation  software,  $3  to
$9  were  returned  in  incremental  revenue  and  costs  savings.
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But  why  is  it  so  important  to  determine  the  3D  structure
f  a  macromolecule  such  as  a  protein?  Answer:  the  way  in
hich  the  structure  is  linked  to  the  sequence  and  the  func-
ion  is  of  fundamental  importance.  This  is  what  we  may  call
he  structural  biology  dogma.  Thus,  a protein  that  is  not  in
ts  native  conformation  will  in  general  not  show  its  expected
iological  activity  or  function.  On  the  other  hand,  a  given
rotein  sequence  will  always  fold  into  the  same  conforma-
ion  under  the  same  conditions.
Nevertheless,  beyond  the  architecture  of  a  single
rotein,  proteins  interact  with  partners,  such  as  other
io-macromolecules  and  ligands  to  exert  their  functions.
peciﬁc  molecular  recognition  of  proteins  as  targets,  and
mall  molecules  as  ligands  adopts  a  special  interest  given  the
ossibility  to  modify,  suppress  or  modulate  the  activity  of  a
iven  protein  through  non-endogenous,  artiﬁcial  ligands.
A  druggable  target  is  one  that  is  capable  of  binding  to
he  drug  and  whose  activity  can  be  modulated  by  it.  The
arget  may  be  known  or  may  need  to  be  predicted.  Impor-
ant  properties  in  the  recognition  of  a  druggable  target  by
 ligand  are  the  afﬁnity  and  the  selectivity  (the  ability  of
he  ligand  to  differentiate  between  different  acceptors).
olecular  recognition  uses  principles  of  hydrophobicity,
teric,  physicochemical,  and  electrostatic  complementarity.
n  addition,  internal  dynamics  and  mutually  induced  confor-
ational  changes  may  take  place  upon  the  binding  between
he  target  and  the  drug  molecules  that  adopt  ‘‘bioactive’’
onformations.  In  order  to  improve  then  the  drug  discov-
ry  process,  the  internal  motions  of  the  partners  involved  in
he  interaction  need  to  be  described  and  taken  into  account,
ncluding  allosteric  effects.  All  this  knowledge  contributes
o  the  understanding  of  the  molecular  basis  of  disease.
It  is  useful  to  know  that  the  chemical  space  of  poten-
ial  pharmacologically  active  molecules  may  contain  around
062 molecules.  The  known  chemicals  are  in  the  order  of
07. The  known  drugs  occupy  thus  10-55 of  the  ‘‘active’’
hemical  space.  A  long  way  to  go,  in  any  case!  Now,  there
 by Masson Doyma Me´xico S.A. This is an open access article under
d/4.0/).
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264  
re  several  approaches  and  levels  for  the  rational  discov-
ry,  design,  and  development  of  de  novo  pharmaceuticals.
tructure-based  drug  design  applies  when  the  structure  of
he  biological  target  is  known.  For  that  purpose,  mining  of
rugs  is  accomplished  through  access  to  libraries  of  drug-
ike  chemical  compounds  stored  in  public  and  corporate
atabases.  These  databases  represent  an  enormous  diver-
ity  of  tens  of  millions  of  potential  drug  molecules  (enzyme
ctivators  and  inhibitors,  receptor  agonists  and  antagonists,
on  channel  openers  or  blockers,  modulators  that  bind  to
econdary  sites)  and  their  effects.  However,  it  is  still  neces-
ary  to  estimate  their  ADME-Tox  pharmacokinetic  properties
rom  the  chemical  structure  (Absorption/solubility),  Distri-
ution,  Metabolism,  Excretion  -- Toxicity  (carcinogenicity,
utagenicity,  oral  LD50,  developmental  toxicity  potential,
kin  sensitization)  in  order  to  ﬁlter  out  those  compounds
hat  do  not  possess  the  appropriate  properties.  The  searched
ncrease  in  speciﬁcity  allows  the  drug  to  bind  to  the  desired
arget  and  binding  pocket(s),  reducing  adverse  drug  reac-
ions.  Subsequently,  virtual  screening  with  computers  of
he  results  of  data  mining  through  ligand  docking  leads  to  the
ormation  of  the  protein-ligand  complexes  and  an  estimation
f  their  afﬁnity.  Of  course,  binding  site  identiﬁcation  must
ome  previously  to  the  docking  of  the  ligand  to  it.  Medici-
al  chemists  play  a  fundamental  role  in  the  optimization  of
n  initial  compound  from  hit  to  lead  since  their  knowledge
oints  to  compounds  that  can  be  realistically  synthesized.
nother  aspect  that  must  be  taken  into  consideration  more
ften  is  that  it  is  the  metabolite(s)  of  the  drug  that  actu-
lly  binds  to  the  intended  target  molecules  and  not  the
dministered  parent  molecule.
When  the  structure  of  the  receptor  molecule  is  unknown,
hen  ligand-based  design  is  used  based  on  the  compounds
inding  to  the  biological  target  of  choice.  In  such  situ-
tion,  the  search  for  a  pharmacophore,  i.e.  a  schematic
odel  of  the  compound  with  the  structural  and  physico-
hemical  properties  needed  to  bind  and  exert  the  desired
ffect  on  the  target,  is  required.  The  ligand-based  design
ay  also  lead  to  mapping  the  receptor  binding  site.  In
omplement  to  the  ligand-based  approach,  a  quantitative
tructure-activity  relationship  (QSAR)  may  also  be  obtained
o  conceive  and  predict  the  activity  of  new  analogs.  Consid-
ring  these  variables  helps  to  increase  enrichment  in  the
it-to-lead  process.  However,  room  for  improvement  exists
n  the  docking  simulations  between  protein  and  ligand.  As
e  know,  water  molecules  play  essential  structural  and  func-
ional  roles  in  biology.  Protein-ligand  complexes  will  contain
ater  molecules  mediating  the  interaction  of  both  partners.
hese  water  molecules  contribute  to  the  formation  and  sta-
ility  of  the  complex.  Until  very  recently,  the  complexes
btained  through  computation  excluded  the  presence  of  the
queous  solvent.  In  order  to  improve  the  determination  of
he  thermodynamic  Gibbs  free  energy  of  complex  formation
n  solution  required  for  obtaining  the  protein-ligand  bind-
ng  afﬁnity,  a  solvated  docking  approach  with  an  explicit
reatment  of  water  molecules  needs  to  be  generalized.EDITORIAL
With  the  advent  and  progress  of  computer  power  and
owerful  software,  the  drug  design  cycle  has  been  enor-
ously  optimized.  Even  though  present  computational
ethods  provide  mostly  qualitative  results,  they  contribute
y  eliminating  many  cycles  in  the  drug  design  process.  Suc-
essful  stories  of  computer-assisted  rational  drug  design
bound  nowadays  and  have  led  to  applications  in  the  ﬁeld
f  chemotherapy  in  cancer,  antivirals,  agonists  and  antago-
ists  of  membrane  receptors  and  proteins  (antipsychotics,
ntidepressants).  In  this  issue  of  the  Boletín  Médico  del
ospital  Infantil  the  México  dedicated  to  cancer,  the  arti-
le  by  Prada-Gracia  et  al.  illustrates  the  applications  of
hese  methods  in  drug  design  and  the  implications  for  novel
ancer  therapies.1 Moreover,  an  updated  review  article  by
oreno-Vargas  and  Prada-Gracia  examines  the  computa-
ional  approach  to  drug  discovery  in  the  physiopathology  of
ancer.2
I  have  witnessed  the  different  ﬁelds  of  computer-assisted
rug  design,  structural  bioinformatics,  and  cheminformat-
cs  go  a  long  way  since  the  early  1990s  when  I  was  doing
ostdoctoral  work  at  the  Faculté  de  Pharmacie  of  the
niversité  de  Paris  V--René  Descartes.  Despite  reticence,
oubts,  and  skepticism,  these  ﬁelds  have  ﬁnally  passed  the
ests  of  experience  and  proven  worthy.  It  is  true  that  transla-
ional  medicine  (i.e.  bringing  a  drug  from  bench  to  bedside)
emains  a  costly,  complex  and  time-consuming  process  with
o  guarantee  of  success,  taking  a  drug  at  least  ﬁve  years  to
ake  it  to  the  marketplace  at  the  cost  of  several  billion  dol-
ars.  Nevertheless,  the  computational  approach  will  play  an
ver  increasing  role  in  overcoming  those  bottlenecks.  Then,
harmacogenomics  and  precision  medicine  will  contribute
o  more  efﬁcient  drug  development  and  therapies  destined
o  improve  the  life  and  health  of  patients.
Undeniably,  the  multidisciplinary  rational  drug  discovery
pproach  involving  biologists,  chemists,  physicists,  com-
uter  scientists  and  medical  doctors  does  not  keep  creativity
nd  serendipity  from  playing  a  role,  reminding  us  that
ltimately  ‘‘There  is  no  logical  path  to  these  laws;  only  intu-
tion,  resting  on  sympathetic  understanding  of  experience,
an  reach  them’’  (Albert  Einstein).
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